$264 Thousand is the total value of Founders Fund VI Management, LLC's 3 reported holdings in Q1 2024. The portfolio turnover from Q4 2023 to Q1 2024 was 150.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CYTH | CYCLO THERAPEUTICS INC | $152,932 | -12.6% | 110,023 | 0.0% | 57.89% | +4119.7% | |
| SNAP | New | SNAP INCcl a | $103,894 | – | 9,050 | +100.0% | 39.33% | – |
| NVMI | New | NOVA LTD | $7,331 | – | 4,142 | +100.0% | 2.78% | – |
| Exit | ROIVANT SCIENCES LTD | $0 | – | -1,119,489 | -100.0% | -98.63% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2024-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ROIVANT SCIENCES LTD | 9 | Q4 2023 | 99.0% |
| APPLIED MOLECULAR TRANS INC | 8 | Q3 2023 | 34.0% |
| SNAP INC | 5 | Q1 2024 | 39.3% |
| CYCLO THERAPEUTICS INC | 3 | Q2 2024 | 100.0% |
| OSCAR HEALTH INC | 2 | Q1 2022 | 79.6% |
| NOVA LTD | 1 | Q1 2024 | 2.8% |
View Founders Fund VI Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View Founders Fund VI Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.